Home » Authors » Douglas Merrill

Articles by Douglas Merrill

Evotec's Licensing Model Keeps It A Step Ahead In Difficult Market

Sep. 4, 2002

By Douglas Merrill

Evotec's Licensing Model Keeps It A Step Ahead In Difficult Market

Sep. 4, 2002

By Douglas Merrill

MediGene Divesting Program In Cardiology Drug Discovery

Aug. 21, 2002

By Douglas Merrill

MediGene Divesting Program In Cardiology Drug Discovery

Aug. 21, 2002

By Douglas Merrill

Start-Up NascaCell's Platform Speeding Drug Discovery

Aug. 14, 2002

By Douglas Merrill

Start-Up NascaCell's Platform Speeding Drug Discovery

Aug. 14, 2002

By Douglas Merrill

Ganymed Oversubscribed In EUR10 Million First Round

July 31, 2002

By Douglas Merrill

Ganymed Oversubscribed In EUR10 Million First Round

July 31, 2002

By Douglas Merrill

MBT Munich Starts Study Of Agent With Cancer Applications

July 24, 2002

By Douglas Merrill

MBT Munich Starts Study Of Agent With Cancer Applications

July 24, 2002

By Douglas Merrill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...